BrilliA Inc (BRIA)

Orchard Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023
Net Income	2.82	3.28	4.35
Depreciation & Amortization	0.46	0.2	0.22
Loss (Gain) From Sale of Investments	0	0.24	0.02
Other Operating Activities	0.7	0.41	0.79
Change in Accounts Receivable	2.02	-5.17	3.23
Change in Inventory	-0.19	-1.36	4
Change in Accounts Payable	-11.17	3.38	-1.53
Change in Unearned Revenue	0.84	-0.84	-
Operating Cash Flow	-4.52	0.14	11.08
Operating Cash Flow Growth	-	-98.70%	-
Capital Expenditures	-0.07	-0.06	-0.01
Other Investing Activities	-0.82	0.11	0.01
Investing Cash Flow	-0.89	0.05	-0
Short-Term Debt Issued	0	0.61	-
Total Debt Issued	0	0.61	-
Short-Term Debt Repaid	-0.01	-	-0.35
Long-Term Debt Repaid	-0.36	-0.2	-0.21
Total Debt Repaid	-0.37	-0.2	-0.56
Net Debt Issued (Repaid)	-0.36	0.41	-0.56
Issuance of Common Stock	7.19	-	-
Common Dividends Paid	-	-3.15	-6.3
Other Financing Activities	-0.12	-0.01	-0.03
Financing Cash Flow	6.71	-2.75	-6.89
Foreign Exchange Rate Adjustments	0.02	-0.11	-0.04
Net Cash Flow	1.32	-2.66	4.15
Free Cash Flow	-4.59	0.09	11.07
Free Cash Flow Growth	-	-99.21%	-
Free Cash Flow Margin	-7.13%	0.15%	20.92%
Free Cash Flow Per Share	-0.20	0.00	0.49
Cash Interest Paid	0.12	0.01	0.03
Cash Income Tax Paid	0.03	0.2	0.12
Levered Free Cash Flow	-5.98	-	-
Unlevered Free Cash Flow	-5.67	-	-
Change in Net Working Capital	8.56	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q